PEDS Advance Access originally published online on May 4, 2004
Protein Engineering Design and Selection 2004 17(4):357-366; doi:10.1093/protein/gzh039
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody
Affimed Therapeutics AG, Im Neuenheimer Feld 582, D-69120 Heidelberg, Germany
1 To whom correspondence should be addressed. E-mail: s.kipriyanov{at}affimed.com
Bispecific single-chain Fv antibodies comprise four covalently linked immunoglobulin variable (VH and VL) domains of two different specificities connected by three linkers. When assembled in the order VHA–linker1–VLB–linker2–VHB–linker3–VLA, the single-chain molecule either folds head-to-tail with the formation of a diabody-like structure, a so-called bispecific single-chain diabody, or forms a homodimer that is twice as large, a so-called tandem diabody. The formation of the tandem diabody is determined by the association of complementary VH and VL domains located on different polypeptide chains, and depends on the length and probably the amino acid composition of the three linkers joining the variable domains. We generated a number of single-chain constructs using four VH and VL domains specific either for human CD3, a component of T-cell receptor (TCR) complex, or for CD19, a human B-cell antigen, separated by different rationally designed peptide linkers of 6–27 amino acid residues. The generated bispecific constructs were expressed in bacterial periplasm and their molecular forms, antigen-binding properties, stability, and T-cell proliferative and anti-tumor activities were compared. Using peripheral blood mononuclear cell cultures from patients suffering from B-cell chronic lymphocytic leukemia, we demonstrated that the tandab-mediated activation of autologous T cells and depletion of malignant cells correlates with the stability of the recombinant molecule and with the distance between the CD19 and CD3 binding sites.
Received February 13, 2004; revised April 6, 2004; accepted April 16, 2004.
Edited by Phillipp Holliger
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G.-B. Kim, Z. Wang, Y. Y. Liu, S. Stavrou, A. Mathias, K.J. Goodwin, J. M. Thomas, and D. M. Neville A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin Protein Eng. Des. Sel., September 1, 2007; 20(9): 425 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-Y. Xiong, A. Natarajan, X.-B. Shi, G. L. Denardo, and S. J. Denardo Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding Protein Eng. Des. Sel., August 1, 2006; 19(8): 359 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Asano, Y. Sone, K. Makabe, K. Tsumoto, H. Hayashi, Y. Katayose, M. Unno, T. Kudo, and I. Kumagai Humanization of the Bispecific Epidermal Growth Factor Receptor x CD3 Diabody and Its Efficacy as a Potential Clinical Reagent. Clin. Cancer Res., July 1, 2006; 12(13): 4036 - 4042. [Abstract] [Full Text] [PDF]
|
|